Compound Reduces Sepsis Inflammation in Mice
Researchers report a modified tanshinone IIA derivative, A12, lowers inflammatory signaling in mouse models of sepsis by targeting the protein DNAJC9.
Updated on Nov. 5, 2026 in Life Sciences
Scientists have developed A12, a covalent inhibitor derived from tanshinone IIA, that reduces inflammation in mouse models of sepsis. The compound showed roughly 100-fold greater anti-inflammatory activity than its parent compound and extended survival in a cecal ligation and puncture model.
Why it matters
Excessive inflammation contributes to organ injury in sepsis, a condition for which targeted anti-inflammatory options remain limited. The work identifies a specific molecular target, offering a potential route for future drug development.
The findings come from cell experiments and a lipopolysaccharide-induced mouse model, with A12 showing approximately 100-fold greater anti-inflammatory activity than tanshinone IIA and inhibiting cytokine release at submicromolar concentrations. Human safety and efficacy remain unestablished, as all reported results derive from preclinical models.
The players
Acta Pharmaceutica Sinica B
A peer-reviewed journal publishing pharmaceutical and biomedical research, including this study on the A12 compound.
DNAJC9
A co-chaperone protein in the heat shock protein system that was identified as the direct molecular target of A12.
The details
Researchers chemically modified tanshinone IIA, a compound from Salvia miltiorrhiza, by adding a group designed to form a covalent bond with a target protein, then screened and optimized the resulting compounds to identify A12. Oral A12 reduced TNF-α, IL-6, and IL-12 in mice and extended survival in a cecal ligation and puncture sepsis model, and the team linked the effect to a covalent bond at cysteine 243 of DNAJC9, a co-chaperone in the heat shock protein system.
Timeline
June 2026: Study published in Acta Pharmaceutica Sinica B, volume 16, issue 10.
November 5, 2026: News-Medical published coverage of the study.
The Big Picture
The study builds on tanshinone IIA, a traditional-medicine-derived compound whose anti-inflammatory effects have long been studied but limited in potency. By converting it into a covalent inhibitor that acts on DNAJC9, the work points toward a targeted approach to inflammation control in sepsis rather than broad immune suppression.
Any future treatment derived from this work would still need human clinical trials before it could reach patients, so no immediate change to sepsis care is possible. For now, the finding is a laboratory lead that could eventually inform new anti-inflammatory drug design.
The takeaway
A targeted molecular approach to sepsis inflammation, identifying a specific protein rather than broadly suppressing the immune response, is a useful model for future drug research. Readers should note that these results come from animal and cell studies and have not yet been tested in people.
Further reading
Explore more research in Life Sciences for context on how molecular targets are being mapped to inflammatory diseases.
More information
Read the full Acta Pharmaceutica Sinica B journal article on the publisher's site.
Source note: This article includes information reported by News-Medical.
